hVIVO looking healthier thanks to pandemic

While the effects of the pandemic on businesses are starting to ease, some companies made great leaps forward over the last couple of years. One of these is hVivo (formerly Open Orphan), the Cathal Friel-backed contract research organisation. Despite the high price/earnings rating for the shares, they look to be heading in the right direction.

Open Orphan is a specialist contract research organisation which, with the acquisition of hVivo at the end of 2019 (and the subsequent name change from Open Orphan to hVivo), has developed into a leading tester of vaccines for infectious and respiratory diseases as well as of therapeutics using human challenge clinical trials.

The group provides end-to-end early clinical development services to a number of big pharma companies, which currently include four of the top 10 global biopharma businesses by scale.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Understanding the different types of Clinical Trials

    Clinical trials are essential for advancing medicine, enhancing drug discovery, and improving patient safety. There are two main types of clinical trials: observational and interventional. Understanding these types helps researchers conduct thorough, safe, effective, and compliant

    hVIVO plc

    Hvivo reports record revenue in first half of the year

    Hvivo, a Dublin and London-listed pharmaceutical services company, reported a record revenue for the first half of the year, continuing its momentum in the market. Specialising in testing infectious and respiratory disease products, Hvivo announced that

    hVIVO plc

    hVIVO materially increases revenue, further improving margins

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has provided a trading update for the six-month period ended 30 June 2024. Highlights

    hVIVO plc

    The importance of clinical trials in medical research

    Clinical trials are a critical component of medical research, involving the testing of pharmaceutical drugs, medical devices, or other treatments on human participants to evaluate their efficacy and safety. These trials play a crucial role in

    hVIVO plc

    Accelerating vaccine development to combat the tripledemic

    The recent rise of the “tripledemic” – the simultaneous spread of the influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) – is posing significant risks, especially to older adults and those with chronic conditions or compromised

    hVIVO plc

    hVIVO plc announce Phase 2b Influenza Field Study Contract

    Highlights ·    hVIVO to enrol up to 1,000 healthy volunteers as part of a multicenter field study testing an influenza drug candidate, with hVIVO selected as the sole UK clinical site ·    Largest field study contract supporting a new income

    hVIVO plc

    The last smallpox outbreak and the future of vaccination

    Fifty years ago this month, India experienced its final seasonal smallpox epidemic. Nearly 200,000 infections were recorded, resulting in over 30,000 deaths. By May 1975, the last case of smallpox in India was diagnosed, and in

    hVIVO plc

    Travellers vaccines and the role of Human Challenge Trials

    A travellers’ vaccine is administered to individuals from non-endemic regions before they travel to areas where certain diseases are prevalent. These vaccines are crucial for travel medicine, protecting travellers and preventing the importation of vaccine-preventable diseases

    hVIVO plc

    hVIVO secures contract for Omicron characterisation study

    In June 2024, hVIVO announced a £2.5 million contract with a mid-sized pharmaceutical company to launch an Omicron characterisation study. This study aims to determine a dose of hVIVO’s Omicron BA.5 challenge agent that establishes a

    hVIVO plc

    hVIVO signs £2.5m contract for Omicron characterisation study

    hVIVO plc (LON:HVO), a fast growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed a £2.5m contract with a mid-sized pharmaceutical company

    hVIVO plc

    Clinical Trial participation and eligibility requirements

    People who haven’t had the opportunity to participate in a clinical trial often wonder about eligibility criteria. Each trial has its own goals and purposes, so the inclusion criteria vary. Many trials require participants with specific

    hVIVO plc

    A complete guide to Clinical Trials

    Clinical trials play a vital role in the discovery, testing, and eventual marketing of new drugs. Over a million individuals participated in clinical trials during 2022/23, involving more than 6,000 studies. Understanding eligibility criteria for clinical